Search Results - "Schaft, Jorien"

Dupilumab is very effective in a large cohort of difficult‐to‐treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry by Ariëns, Lieneke F. M., Schaft, Jorien, Bakker, Daphne S., Balak, Deepak, Romeijn, Margreet L. E., Kouwenhoven, Tessa, Kamsteeg, Marijke, Giovannone, Barbara, Drylewicz, Julia, Amerongen, Cynthia Catalina Aurora, Delemarre, Evelien M., Knol, Edward F., Wijk, Femke, Nierkens, Stefan, Thijs, Judith L., Schuttelaar, Marie L. A., Bruin‐Weller, Marjolein S.

“…Introduction Dupilumab has recently been approved for the treatment of moderate to severe atopic dermatitis (AD) in adults. Daily practice data on dupilumab…”
Get full text

Two‐year drug survival of dupilumab in a large cohort of difficult‐to‐treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: Results from the BioDay registry by Spekhorst, Lotte S., Ariëns, Lieneke F.M., Schaft, Jorien, Bakker, Daphne S, Kamsteeg, Marijke, Oosting, Albert J., Ridder, Ilona, Sloeserwij, Annemiek, Romeijn, Geertruida L.E., Graaf, Marlies, Haeck, Inge, Thijs, Judith L., Schuttelaar, Marie L.A., de Bruin‐Weller, Marjolein S.

Get full text

Early identification of atopic dermatitis patients in need of systemic immunosuppressive treatment by Bakker, Daphne S., Drylewicz, Julia, Nierkens, Stefan, Knol, Edward F., Giovannone, Barbara, Delemarre, Eveline M., Schaft, Jorien, Balak, Deepak M. W., Bruin‐Weller, Marjolein S., Thijs, Judith L.

Get full text

Dupilumab in atopic dermatitis: rationale, latest evidence and place in therapy by Ariëns, Lieneke F.M., Bakker, Daphne S., van der Schaft, Jorien, Garritsen, Floor M., Thijs, Judith L., de Bruin-Weller, Marjolein S.

“…Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases. The prevalence of AD is increasing and is currently estimated at 10–20% in…”
Get full text

Serum vitamin D status in adult patients with atopic dermatitis: Recommendations for daily practice by van der Schaft, Jorien, MD, PhD, Ariens, Lieneke F.M., MD, Bruijnzeel-Koomen, Carla A.F.M., MD, PhD, de Bruin-Weller, Marjolein S., MD, PhD

Get full text

Long-term follow-up and treatment outcomes of conjunctivitis during dupilumab treatment in patients with moderate-to-severe atopic dermatitis by Achten, Roselie, Bakker, Daphne, Ariens, Lieneke, Lans, Amanda, Thijs, Judith, van der Schaft, Jorien, de Boer, Joke, Balak, Deepak, de Graaf, Marlies, van Luijk, Chantal, de Bruin-Weller, Marjolein

“…Dupilumab is the first biologic treatment for atopic dermatitis (AD), and its effectiveness and safety are proven.1 Although conjunctivitis is the most…”
Get full text

First experience with extended release tacrolimus in the treatment of adult patients with severe, difficult to treat atopic dermatitis: Clinical efficacy, safety and dose finding by van der Schaft, Jorien, van Schaik, Ron H.N, van Zuilen, Arjan D, Hijnen, Dirk-Jan, Berg, Maarten ten, van den Broek, Marcel P.H, Bruijnzeel-Koomen, Carla A.F.M, de Bruin-Weller, Marjolein S

Get full text

Economic Burden of Adult Patients with Moderate to Severe Atopic Dermatitis Indicated for Systemic Treatment by Ariëns, Lieneke F M, van Nimwegen, Kirsten J M, Shams, Marjan, de Bruin, Digna T, van der Schaft, Jorien, van Os-Medendorp, Harmieke, De Bruin-Weller, Marjolein

“…Given the introduction of new therapies targeting specific immune pathways for atopic dermatitis (AD), information on the economic burden of AD patients is…”
Get full text

Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry by Ariëns, Lieneke F M, Bakker, Daphne S, Spekhorst, Lotte S, Van der Schaft, Jorien, Thijs, Judith L, Haeck, Inge, Flinterman, Annebeth E, Kamsteeg, Marijke, Schuttelaar, Marie L A, De Bruin-Weller, Marjolein S

“…Dupilumab treatment improves signs, symptoms, and quality of life in patients with moderate-to-severe atopic dermatitis. This study evaluated the impact of…”
Get full text

Successful Treatment with Dupilumab in a Patient with Severe, Difficult to Treat Atopic Dermatitis: Beware of Symptomatic Adrenal Insufficiency due to Abrupt Discontinuation of Potent Topical Corticosteroids by Ariëns, Lieneke F M, van der Schaft, Jorien, Stades, Aline M E, van de Woestijne, Anthonie A, De Bruin-Weller, Marjolein S

Get full text

Risk of Non-melanoma Skin Cancer in Patients with Atopic Dermatitis Treated with Oral Immunosuppressive Drugs by Garritsen, Floor M, van der Schaft, Jorien, van den Reek, Juul M, Politiek, Klaziena, van Os-Medendorp, Harmieke, van Dijk, Marijke, Hijnen, Dirk J, de Graaf, Marlies, Bruijnzeel-Koomen, Carla A, de Jong, Elke M, Schuttelaar, Marie-Louise A, Bruin-Weller, Marjolein S

“…There is uncertainty about the risk of developing non-melanoma skin cancer (NMSC), including basal cell carcinoma and squamous cell carcinoma (SCC), in…”
Get full text

Allopurinol Co-prescription Improves the Outcome of Azathioprine Treatment in Chronic Eczema by Garritsen, Floor M, van der Schaft, Jorien, de Graaf, Marlies, Hijnen, Dirk Jan, Bruijnzeel-Koomen, Carla A F, van den Broek, Marcel P H, De Bruin-Weller, Marjolein S

Get full text

Confirmation of multiple endotypes in atopic dermatitis based on serum biomarkers by Bakker, Daphne S., Nierkens, Stefan, Knol, Edward F., Giovannone, Barbara, Delemarre, Eveline M., van der Schaft, Jorien, van Wijk, Femke, de Bruin-Weller, Marjolein S., Drylewicz, Julia, Thijs, Judith L.

“…Atopic dermatitis (AD) is a highly heterogeneous disease, both clinically and biologically, whereas patients are still being treated according to a…”
Get full text

When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council by Simpson, Eric L., Bruin-Weller, Marjolein, Flohr, Carsten, Ardern-Jones, Michael R., Barbarot, Sebastien, Deleuran, Mette, Bieber, Thomas, Vestergaard, Christian, Brown, Sara J., Cork, Michael J., Drucker, Aaron M., Eichenfield, Lawrence F., Foelster-Holst, Regina, Guttman-Yassky, Emma, Nosbaum, Audrey, Reynolds, Nick J., Silverberg, Jonathan I., Schmitt, Jochen, Seyger, Marieke M.B., Spuls, Phyllis I., Stalder, Jean-Francois, Su, John C., Takaoka, Roberto, Traidl-Hoffmann, Claudia, Thyssen, Jacob P., van der Schaft, Jorien, Wollenberg, Andreas, Irvine, Alan D., Paller, Amy S.

“…Although most patients with atopic dermatitis (AD) are effectively managed with topical medication, a significant minority require systemic therapy. Guidelines…”
Get full text

Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry by Ariëns, Lieneke F.M., van der Schaft, Jorien, Spekhorst, Lotte S., Bakker, Daphne S., Romeijn, Geertruida L.E., Kouwenhoven, Tessa A., Kamsteeg, Marijke, Voorberg, Angelique N., Oosting, Albert J., de Ridder, Ilona, Sloeserwij, Annemieke, Haeck, Inge, Thijs, Judith L., Schuttelaar, Marie L.A., de Bruin-Weller, Marjolein S.

“…Real-life data on long-term effectiveness and safety of dupilumab in atopic dermatitis patients are limited. To study 52-week effectiveness and safety of…”
Get full text

Dermpath & Clinic: Pemphigus herpetiformis with vacuolar interface dermatitis and autoantibodies against desmoglein 1 and 3 by Van Rhijn, Bram D., Van Der Schaft, Jorien, Horvath, Barbara, Van Dijk, Marijke R., Pas, Hendri H.

Get full text

Dupilumab facial redness: Positive effect of itraconazole by de Beer, Fleur S.A., Bakker, Daphne S., Haeck, Inge, Ariens, Lieneke, van der Schaft, Jorien, van Dijk, Marijke R., de Bruin-Weller, Marjolein S.

Get full text

Towards personalized treatment in atopic dermatitis by van der Schaft, Jorien, Thijs, Judith L, Garritsen, Floor M, Balak, D, de Bruin-Weller, Marjolein S

“…For many years, oral immunosuppressive drugs such as cyclosporine A, azathioprine, mycophenolic acid, and methotrexate were the only treatment options, in…”
Get more information

Dupilumab after the 2017 approval for the treatment of atopic dermatitis: whatʼs new and whatʼs next? by van der Schaft, Jorien, Thijs, Judith L, de Bruin-Weller, Marjolein S, Balak, Deepak M.W

“…PURPOSE OF REVIEWThe IL-4/13 antagonist dupilumab was approved in 2017 as the first biologic for atopic dermatitis. Here, we comprehensively review compelling…”
Get full text

Serum creatinine levels during and after long-term treatment with cyclosporine A in patients with severe atopic dermatitis by van der Schaft, Jorien, van Zuilen, Arjan D, Deinum, Joukje, Bruijnzeel-Koomen, Carla A F M, de Bruin-Weller, Marjolein S

“…Safety data with respect to kidney function during long-term treatment with cyclosporine A (CsA) in patients with atopic dermatitis is limited. Data on serum…”
Get full text